BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sehouli J, Papanikolaou G, Braicu E, Pietzner K, Neuhaus P, Fotopoulou C. Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer. Ann Surg Oncol 2012;19:1326-33. [DOI: 10.1245/s10434-011-2134-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Turco LC, Ferrandina G, Vargiu V, Cappuccio S, Fagotti A, Sallustio G, Scambia G, Cosentino F. Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature. Ann Transl Med 2020;8:1687. [PMID: 33490199 DOI: 10.21037/atm-20-4448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Fotopoulou C, Haidopoulos D. Extraperitoneal en bloc intestinal resection as palliative surgery for treatment refractory bowel obstruction in ovarian cancer relapse. Int J Gynecol Cancer 2020;30:711. [PMID: 31992600 DOI: 10.1136/ijgc-2019-001058] [Reference Citation Analysis]
3 Fagotti A, Conte C, Stollagli F, Gallotta V, Salutari V, Bottoni C, Bruno M, Zannoni GF, Scambia G. Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience". Int J Gynecol Cancer 2018;28:1569-75. [PMID: 30157167 DOI: 10.1097/IGC.0000000000001350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Fotopoulou C, Gabra H, Blagden SP. Surgical and Medical Management of Epithelial Ovarian Cancer. Dewhurst's Textbook of Obstetrics & Gynaecology 2018. [DOI: 10.1002/9781119211457.ch63] [Reference Citation Analysis]
5 Petrillo M, Nero C, Carbone V, Bruno M, Scambia G, Fagotti A. Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. Ann Surg Oncol 2018;25:247-54. [PMID: 29134372 DOI: 10.1245/s10434-017-6235-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
6 Chan TW, Latifi N, Weiss A, Blair SL. Management of Perioperative Medications Including Steroids, Growth Factors, and Hormone Receptors. Surgical Emergencies in the Cancer Patient 2017. [DOI: 10.1007/978-3-319-44025-5_24] [Reference Citation Analysis]
7 Nixon K, Fotopoulou C. Diagnosis and Management of Epithelial Ovarian Cancer. Handbook of Gynecology 2017. [DOI: 10.1007/978-3-319-17798-4_1] [Reference Citation Analysis]
8 Daniele G, Lorusso D, Scambia G, Cecere SC, Nicoletto MO, Breda E, Colombo N, Artioli G, Cannella L, Lo Re G, Raspagliesi F, Maltese G, Salutari V, Ferrandina G, Greggi S, Baldoni A, Bergamini A, Piccirillo MC, Tognon G, Floriani I, Signoriello S, Perrone F, Pignata S. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol 2017;144:256-9. [PMID: 27993479 DOI: 10.1016/j.ygyno.2016.12.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
9 Nixon K, Fotopoulou C. Diagnosis and Management of Epithelial Ovarian Cancer. Handbook of Gynecology 2016. [DOI: 10.1007/978-3-319-17002-2_1-1] [Reference Citation Analysis]
10 Petrillo M, Paris I, Vizzielli G, Amadio G, Cosentino F, Salutari V, Scambia G, Fagotti A. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study. Ann Surg Oncol 2015;22 Suppl 3:S952-8. [PMID: 26036187 DOI: 10.1245/s10434-015-4651-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
11 Salani R, O'Malley DM, Copeland LJ, Cohn DE, Backes FJ, Fowler JM, Eisenhauer EL. Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer--a phase 1 study. Int J Gynecol Cancer 2014;24:682-6. [PMID: 24651631 DOI: 10.1097/IGC.0000000000000107] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
12 Fotopoulou C, Braicu EI, Kwee SL, Kuhberg M, Richter R, Pietzner K, Feldheiser A, Bahra M, Schmidt SC, Sehouli J. Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome. Int J Gynecol Cancer 2013;23:1495-500. [PMID: 24189059 DOI: 10.1097/IGC.0b013e31829f81ca] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chéreau E, Lambaudie E, Houvenaeghel G. Morbidity of Surgery After Neoadjuvant Chemotherapy Including Bevacizumab for Advanced Ovarian Cancer. Int J Gynecol Cancer 2013;23:1326-30. [DOI: 10.1097/igc.0b013e31829dc923] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]